{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:11:24Z","timestamp":1779297084494,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejca.2026.116740","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T20:50:13Z","timestamp":1776027013000},"page":"116740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer"],"prefix":"10.1016","volume":"240","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1813-0423","authenticated-orcid":false,"given":"Dries","family":"Develtere","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros","family":"Tsantoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timoth\u00e9e","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejca.2026.116740_bib1","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.euo.2025.03.007","article-title":"Oncological outcomes in bacillus calmette-gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer patients: a systematic review on current treatment strategies and future perspectives","volume":"8","author":"Longoni","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116740_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","article-title":"ALBAN (GETUG-AFU 37): a phase III, randomized, open-label international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Gu\u00e9rin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)","volume":"37","author":"Roupret","year":"2026","journal-title":"Ann Oncol"},{"issue":"10516","key":"10.1016\/j.ejca.2026.116740_bib3","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejca.2026.116740_bib4","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ejca.2026.116740_bib5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.annonc.2025.10.015","article-title":"Combination with BCG induction and maintenance therapy for high-risk non-muscle invasive bladder cancer","volume":"37","author":"Meeks","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116740_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-25-02670","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) and beyond: is systemic Immunotherapy for BCG-na\u00efve non\u2013muscle-invasive bladder cancer progress or overreach?","author":"Kamat","year":"2026","journal-title":"J Clin Oncol"},{"issue":"7172","key":"10.1016\/j.ejca.2026.116740_bib7","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","article-title":"Survival probabilities (the Kaplan-Meier method)","volume":"317","author":"Bland","year":"1998","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ejca.2026.116740_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41571-020-0368-0","article-title":"Informative censoring \u2014 a neglected cause of bias in oncology trials","volume":"17","author":"Templeton","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116740_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113942","article-title":"Equal censoring but still informative: when the reasons for censoring differ between treatment arms","volume":"201","author":"Olivier","year":"2024","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2026.116740_bib10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(24)00722-8","article-title":"The BREAKING-ICE App: an interactive journey into informative censoring","volume":"26","author":"Olivier","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116740_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Method"},{"issue":"1","key":"10.1016\/j.ejca.2026.116740_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Method"},{"key":"10.1016\/j.ejca.2026.116740_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2025.102397","article-title":"LUNAR: full moon or eclipse? an exploration into tumor treating fields in lung cancer","volume":"56","author":"Olivier","year":"2025","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ejca.2026.116740_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114192","article-title":"CDK4\/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms","volume":"207","author":"Haslam","year":"2024","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2026.116740_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2025.12.022","article-title":"Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Gu\u00e9rin (BCG) in BCG-na\u00efve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials","volume":"89","author":"Scilipoti","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2026.116740_bib16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.04.044","article-title":"Informative censoring of surrogate end-point data in phase 3 oncology trials","volume":"153","author":"Gilboa","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2026.116740_bib17","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S1470-2045(21)00473-3","article-title":"Inappropriate censoring in Kaplan-Meier analyses","volume":"22","author":"Fojo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2026.116740_bib18","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.55630","article-title":"Reanalysis of Urothelial Cancer Chemoimmunotherapy Trials With Differential Censoring","volume":"8","author":"Meirson","year":"2025","journal-title":"JAMA Netw Open"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926005216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:23:25Z","timestamp":1779294205000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926005216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":18,"alternative-id":["S0959804926005216"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116740","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Censoring patterns and inconsistent results in checkpoint inhibitor and adjuvant BCG trials for high-risk bladder cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116740","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116740"}}